<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Indaptus Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc</link>
<description>Latest news and press releases for Indaptus Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 29 Dec 2025 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/indaptus-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583c778dffbe2df0fcd5d.webp</url>
<title>Indaptus Therapeutics Inc</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc</link>
</image>
<item>
<title>Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-enters-6-million-securities-120000903</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-enters-6-million-securities-120000903</guid>
<pubDate>Mon, 29 Dec 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces it has entered into a $6 million securities purchase agreement with investor, David E. Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been appointed Indaptus’ Co-Chief Executive Officer and Chairman of th</description>
</item>
<item>
<title>Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-chief-scientific-officer-130000510</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-chief-scientific-officer-130000510</guid>
<pubDate>Mon, 17 Nov 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that Michael Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 3rd Donor Selection & Cell Source Summit, taking place November 19–20, 2025, in San Diego, California. Dr. Newman’s presentation, titled, “Creating Super Donor Cells P</description>
</item>
<item>
<title>Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-third-quarter-133000984</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-third-quarter-133000984</guid>
<pubDate>Wed, 12 Nov 2025 13:30:00 GMT</pubDate>
<description>NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the third quarter ended September 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “We have completed the Safety Lead-In cohort, dosing six evaluable participant</description>
</item>
<item>
<title>Indaptus Therapeutics Provides Clinical Update</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-provides-clinical-200100610</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-provides-clinical-200100610</guid>
<pubDate>Thu, 04 Sep 2025 20:01:00 GMT</pubDate>
<description>Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastases Decoy20 combination with PD-1 inhibitor, tislelizumab, demonstrates safety profiles consistent with each agent NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces recent updates for the ongoing INDP-D101</description>
</item>
<item>
<title>Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-present-h-c-200500591</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-present-h-c-200500591</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel. Presentation Date:September 8, 2025Time:3:30pm ETLocation:Kennedy I (4th Floor)Webcast Link:https://journey.ct.events/view/8786ffa5-ad42-43a8-984c-41c7b9e38</description>
</item>
<item>
<title>Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-second-quarter-120000139</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-second-quarter-120000139</guid>
<pubDate>Wed, 13 Aug 2025 12:00:00 GMT</pubDate>
<description>Company Initiates Combination Trial and Strengthens Balance Sheet to Support Continued Clinical ProgressNEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces financial results for the second quarter ended June 30, 2025, and provides a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executiv</description>
</item>
<item>
<title>Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-inc-announces-additional-121400656</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-inc-announces-additional-121400656</guid>
<pubDate>Tue, 01 Jul 2025 12:14:00 GMT</pubDate>
<description>NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the additional sale of approximately $3.4 million in aggregate principal amount of convertible promissory notes and accompanying warrants. Together with a prior sale of $2.3 million of convertible promissory notes and accompanying warrants, the Company raised an aggrega</description>
</item>
<item>
<title>Indaptus Therapeutics Announces Reverse Stock Split</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-announces-reverse-stock-110000567</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-announces-reverse-stock-110000567</guid>
<pubDate>Wed, 25 Jun 2025 11:00:00 GMT</pubDate>
<description>NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Board of Directors has approved a one-for-twenty eight reverse stock split of its common stock that is scheduled to become effective after trading closes on June 26, 2025. Beginning on June 27, 2025, the Company’s common stock will trade on the</description>
</item>
<item>
<title>Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-inc-announces-sale-120000529</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-inc-announces-sale-120000529</guid>
<pubDate>Fri, 13 Jun 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3 million in aggregate principal amount of convertible promissory notes and accompanying warrants. This transaction is being led by a healthcare-focused institutional investor in an ongoing offering in which the Company is seeking to raise u</description>
</item>
<item>
<title>Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-doses-first-patient-120000012</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-doses-first-patient-120000012</guid>
<pubDate>Mon, 02 Jun 2025 12:00:00 GMT</pubDate>
<description>New trial arm to evaluate safety, dosing and preliminary anti-tumor activity of the combination therapy in advanced solid tumorsNEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne’s (formerly known as Bei</description>
</item>
<item>
<title>Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-first-quarter-120000573</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-first-quarter-120000573</guid>
<pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “We made meaningful progress in the first quarter across multiple fronts of our cli</description>
</item>
<item>
<title>Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-founder-chief-scientific-120000610</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-founder-chief-scientific-120000610</guid>
<pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that its Founder and Chief Scientific Officer, Michael Newman, Ph.D., will serve as an Expert Speaker and Chair of Day 2 at the 6th Annual Cytokine-Based Drug Development Summit taking place May 15-16, 2025 in Boston. Dr. Newman will deliver a presentation titled “Pulsed Cytokine Delivery</description>
</item>
<item>
<title>Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-chief-medical-officer-120000238</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-chief-medical-officer-120000238</guid>
<pubDate>Tue, 25 Mar 2025 12:00:00 GMT</pubDate>
<description>NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston. Dr. Waltzman’s panel, titled “Ensuring Effective and Efficient Trials Through Clinical Operations” will be Monday, April 7th from 4:05PM – 4:35PM ET</description>
</item>
<item>
<title>Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-data-demonstrating-120000817</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-data-demonstrating-120000817</guid>
<pubDate>Thu, 20 Mar 2025 12:00:00 GMT</pubDate>
<description>Key findings support weekly induction of immune cell trafficking by Decoy20, a critical factor in effective cancer immunotherapyNEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week’s earnings relea</description>
</item>
<item>
<title>Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-initiates-phase-1-120000013</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-initiates-phase-1-120000013</guid>
<pubDate>Tue, 18 Mar 2025 12:00:00 GMT</pubDate>
<description>New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumorsNEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhib</description>
</item>
<item>
<title>Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-fourth-quarter-113000619</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-reports-fourth-quarter-113000619</guid>
<pubDate>Thu, 13 Mar 2025 11:30:00 GMT</pubDate>
<description>Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectationsEarly signs of potential benefit emerge with some patients demonstrating Stable Disease NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announces financial r</description>
</item>
<item>
<title>Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-expands-patent-portfolio-130000815</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-expands-patent-portfolio-130000815</guid>
<pubDate>Tue, 04 Mar 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) – two diseases that continue to pose majo</description>
</item>
<item>
<title>Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-chief-scientific-officer-130000004</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-chief-scientific-officer-130000004</guid>
<pubDate>Tue, 25 Feb 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that Michael Newman, Founder and Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit, taking place from March 3-5, 2025, in San Diego, California. Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, “Employing Attenuated &</description>
</item>
<item>
<title>Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-receives-approval-from-health-canada-to-expand-clinical-trial-of-decoy20</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-receives-approval-from-health-canada-to-expand-clinical-trial-of-decoy20</guid>
<pubDate>Wed, 05 Feb 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-inc-announces-dollar225-million-private-placement-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/indaptus-therapeutics-inc/news/indaptus-therapeutics-inc-announces-dollar225-million-private-placement-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Mon, 13 Jan 2025 05:00:00 GMT</pubDate>
<description>NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to</description>
</item>
</channel>
</rss>